Citadel Advisors
RCUS icon

Citadel Advisors’s Arcus Biosciences RCUS Stock Holding History

Citadel Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.7M Buy
1,329,935
+1,225,234
+1,170% +$26.5M ﹤0.01% 1909
2025
Q4 		$2.5M Sell
104,701
-190,353
-65% -$3.88M ﹤0.01% 5511
2025
Q3 		$4.01M Sell
295,054
-316,141
-52% -$3.29M ﹤0.01% 4759
2025
Q2 		$4.98M Buy
611,195
+234,097
+62% +$2M ﹤0.01% 4127
2025
Q1 		$2.96M Buy
377,098
+16,504
+5% +$191K ﹤0.01% 4789
2024
Q4 		$5.37M Buy
360,594
+42,723
+13% +$698K ﹤0.01% 3844
2024
Q3 		$4.86M Sell
317,871
-149,292
-32% -$2.35M ﹤0.01% 3989
2024
Q2 		$7.11M Buy
467,163
+112,242
+32% +$1.81M ﹤0.01% 3246
2024
Q1 		$6.7M Buy
354,921
+78,997
+29% +$1.37M ﹤0.01% 3516
2023
Q4 		$5.27M Sell
275,924
-9,923
-3% -$159K ﹤0.01% 3704
2023
Q3 		$5.13M Sell
285,847
-449,782
-61% -$9.04M ﹤0.01% 3606
2023
Q2 		$14.9M Sell
735,629
-1,030,379
-58% -$19.6M ﹤0.01% 2180
2023
Q1 		$32.2M Buy
1,766,008
+1,122,779
+175% +$21.5M 0.01% 1469
2022
Q4 		$13.3M Buy
643,229
+616,739
+2,328% +$17M ﹤0.01% 2442
2022
Q3 		$693K Sell
26,490
-25,393
-49% -$672K ﹤0.01% 7764
2022
Q2 		$1.31M Buy
51,883
+31,975
+161% +$783K ﹤0.01% 6412
2022
Q1 		$628K Sell
19,908
-141,902
-88% -$4.75M ﹤0.01% 8834
2021
Q4 		$6.55M Buy
161,810
+133,722
+476% +$5.19M ﹤0.01% 3827
2021
Q3 		$979K Sell
28,088
-14,061
-33% -$438K ﹤0.01% 8212
2021
Q2 		$1.16M Sell
42,149
-11,003
-21% -$314K ﹤0.01% 7976
2021
Q1 		$1.49M Sell
53,152
-42,361
-44% -$1.47M ﹤0.01% 7113
2020
Q4 		$2.48M Sell
95,513
-20,471
-18% -$495K ﹤0.01% 4910
2020
Q3 		$1.99M Sell
115,984
-254,042
-69% -$5.68M ﹤0.01% 4727
2020
Q2 		$9.15M Buy
370,026
+338,436
+1,071% +$9.13M ﹤0.01% 2331
2020
Q1 		$439K Sell
31,590
-25,494
-45% -$317K ﹤0.01% 6684
2019
Q4 		$577K Buy
57,084
+2,042
+4% +$17.2K ﹤0.01% 6595
2019
Q3 		$501K Sell
55,042
-14,495
-21% -$116K ﹤0.01% 6748
2019
Q2 		$553K Buy
69,537
+52,018
+297% +$521K ﹤0.01% 6665
2019
Q1 		$219K Buy
+17,519
New +$190K ﹤0.01% 8084

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's RCUS Position: Q1 2026 in Review

Citadel Advisors increased its Arcus Biosciences (RCUS) stake by 1,170% in Q1 2026, buying an estimated $26.5M and bringing the position to 1,329,935 shares worth $28.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

Citadel Advisors first reported a position in RCUS in Q1 2019 and has held it in 29 quarters since. The position peaked at $32.2M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Citadel Advisors held 1,329,935 shares of Arcus Biosciences worth $28.7M as of Q1 2026.
  • Citadel Advisors bought 1,225,234 Arcus Biosciences shares in Q1 2026, an estimated $26.5M.
  • Arcus Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1909 holding.
  • Citadel Advisors first reported a position in Arcus Biosciences in Q1 2019 and has held it in 29 quarters since.
  • Citadel Advisors's Arcus Biosciences position peaked at $32.2M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.